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ABSTRACT
Objective: To analyse the effectiveness of hospital-
based case management (CM) in terms of patient-
reported outcomes.
Design: Randomised controlled trial allocating
participants 1 : 1 to either a CM intervention or a
control group. Allocation status was evident to
participants and case managers, but blinded to
researchers.
Setting: Patients were recruited at a Danish surgical
department where the case managers were situated.
Participants: Colorectal cancer patients who were to
undergo further investigation or treatment. Exclusion
criteria were participation in another study, poor Danish
language skills or apparent cognitive impairment. 140
participants were randomised to each group. Recruitment
period was 11 March 2009 to 29 December 2010.
Interventions: Control group patients had usual care.
Intervention group patients had usual care supplemented
by hospital-based CM started at first visit to the out-
patient clinic (before treatment start) and ended 4 weeks
after completed cancer treatment. CM was conducted by
nurse case managers who undertook care pathway
supervision, information dissemination to health
professionals and outreaching patient support.
Outcome measures: Patient-reported global quality of
life measured with the EORTC QLQ-C30 and eight ad hoc,
piloted patient evaluation items assessed at eight, 30 and
52 weeks after randomisation.
Results: The two groups were comparable as to
questionnaire response rates and completed scales/items.
There were no statistically significant group differences on
any of the health-related quality of life subscales at eight,
30 or 52 weeks. In patient evaluations, all point estimates
favoured CM at week 8 and 30; at week 52, 6 of 7
estimates favoured CM.
Conclusions:We found no evidence that CM influenced
colorectal cancer patients’ health-related quality of life.
Patients allocated to CM evaluated their care more
positively than patients receiving usual care.
Trial registration: Clinicaltrials.gov identifier:
NCT00845247.
ARTICLE SUMMARY
Article focus
▪ Case management (CM) models are increas-
ingly engaged in healthcare systems to improve
coordination and continuity of care. Most
programmes are based on case managers who
are experienced nurses engaged full-time to
undertake coordination and support in relation
to individual patients having complex healthcare
needs.
▪ Danish hospital departments treating cancer
patients have been committed to deploy case
managers to improve coordination and continuity
of care. However, scientific evidence of the effect
of CM in this context is scarce.
▪ This article presents results from a randomised
controlled trial (RCT) of nurse CM for colorectal
cancer (CRC) patients.
Key messages
▪ The manual-based CM intervention was con-
ducted by two experienced nurses with regard
to CRC care, the patient perspective and the
Danish healthcare system. Main CM activities
were care pathway supervision and optimisa-
tion, dissemination of patient-specific informa-
tion to general practitioners and other involved
healthcare personnel, and outreaching patient
support.
▪ The CM intervention did not affect patients’
health-related quality of life as measured by the
EORTC QLQ-C30.
▪ The CM intervention showed a tendency to
improve patients’ evaluations of care received.
Strengths and limitations of this study
▪ The CM intervention was manual based, pilot
tested and analysed in an RCT.
▪ The RCT was implemented at only one depart-
ment with the consequence that patients poten-
tially were aware about the purpose of the trial
and their allocation.
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INTRODUCTION
Treatment modalities for cancer evolve rapidly and
cancer survival rates are rising modestly,1 but cancer
patients still suffer from reduced health-related quality
of life (HRQoL) due to their disease, its treatment
and the effects of existential concerns.2 3 Many cancer
patients experience cancer care as episodic and
incoherent as to treatment and care, information pro-
vided and relationship with health professionals.4–7
Importantly, some studies have found a positive correl-
ation between patients’ evaluations of their care and
their HRQoL.8 9
Case management (CM) is often recommended as a
method to improve coordination and continuity of
care for individual patients having complex care needs.
CM is usually conducted by a nurse, the case manager,
who is engaged solely to function as a consistent and
proactive cross-disciplinary member of the healthcare
team.10
CM may be an effective method to improve coordin-
ation and continuity of cancer care and to improve
cancer patients’ HRQoL. However, the effectiveness of
CM in cancer care has been sparsely studied.11 In the
present study, we tested the hypothesis that hospital-
based CM during the treatment period would improve
colorectal cancer (CRC) patients’ HRQoL and their eva-
luations of care.
MATERIALS AND METHODS
Study design
Randomised controlled trial (RCT) allocating CRC
patients to a CM intervention group or a control group
(ratio 1 : 1).
Setting
The Danish healthcare system is primarily tax-ﬁnanced
and grants Danish citizens free access to general practi-
tioner (GP) and public hospital services. Almost all
Danes (98%) are listed with a general practice. The GP
is a gatekeeper with regard to the patient’s referral to
specialist services and functions as a key healthcare
coordinator outside the hospitals.12
The Surgical Department P, Aarhus University Hospital,
Denmark, treats all categories of CRC patients, including
those who suffer from locally advanced or recurrent
disease.
Participants
During the inclusion period from 11 March 2009 to 29
December 2010, all patients at Department P were
assessed for inclusion. We included patients with a diag-
nosis of CRC or ‘a highly probable diagnosis of CRC’
who were to undergo further investigation or treatment
at Department P. Exclusion criteria were participation in
another study (see the Discussion section), poor Danish
language skills or apparent cognitive dysfunction.
Interventions
Control: usual care
Control group patients were treated and cared for as
usual. No designated health professional overlooked the
coordination of health services for this group and they
did not receive telephone calls to systematically assess
their well-being and the coordination and continuity of
their care. In accordance with a paragraph in the
Danish Health Act,13 all control group patients were
given the name and a phone number on an employee at
Department P to grant them easy access to the depart-
ment during the treatment period.
CM intervention
The main aims of the CM intervention, which was con-
ducted supplementary to usual care, were to streamline
individual patients’ care pathways and improve their
well-being and experiences of care. Two experienced
nurses were employed from January 2009 to May 2011 to
work principally as case managers. They initially went
through 2 months of combined additional training and
pilot testing of the manual-based CM intervention and
its appertaining checklists. The case managers had their
ofﬁce at Department P, worked daytime and weekdays
only, were introduced as members of the multidisciplin-
ary team (MDT) and they attended all MDT meetings
where most patients had their cancer staged and treat-
ment options discussed.
A detailed manual, which was pilot tested before the
trial, chronologically described the case managers’
duties. As soon as possible after randomisation, the case
manager scheduled a meeting with the patient to
provide detailed information about the CM services and
availability. In addition, the case manager made a formal
assessment of the patient’s medical and non-medical
condition, his or her expectations regarding care, and
his or her knowledge about the disease and care. An ad
hoc developed needs assessment checklist was used to
guide the conversation.
Throughout the period of treatment, the case
manager regularly (∼every fortnight) telephoned the
patient to assess his or her biopsychosocial status and
screen for barriers to optimal care related to coordin-
ation and awareness of the care plan. Potential inad-
equacies were addressed by involving relevant health
professionals and by increasing the frequency of out-
reach telephone calls.
Patient-speciﬁc information was passed on to the GP
and other relevant health professionals initially and at
transitions between care settings.
Most patients met the case manager at their ﬁrst
meeting in the outpatient clinic which took place a few
days after the patient’s primary colonoscopy or for
patients referred from another CRC specialist to
Department P at the patient’s ﬁrst encounter in the
Department. The duration of active CM varied between
patients but did not terminate before 4 weeks after the
patient had completed planned CRC treatment. There
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was no formal time at which patients could no longer
exercise their option to contact the case manager by
telephone.
Online supplementary ﬁgure S1 provides an overview
of the CM intervention and the usual care in a Pat plot
(ﬁgure 1).14 The CM intervention was pragmatically
designed and operationalised the case manager’s func-
tion as described in the Danish Generic Model for Care
Pathway Programmes.15 The CM intervention and the
methods and feasibility of the trial have been described
in detail elsewhere (paper submitted to BMC Health
Services Research 9 December 2011).
Outcome measures
HRQoL was assessed with the use of the Danish version
of the European Organisation for Research and
Treatment of Cancer Core Quality of Life Questionnaire
V.3.0 (EORTC QLQ-C30), which is a validated, cancer-
speciﬁc, 30-item questionnaire measuring HRQoL on:
one global health status scale, ﬁve functioning scales
and nine symptom scales.16 17 The primary endpoint
of this study was the global health status scale. The
secondary endpoints were scores on the functioning
scales: physical, role, cognitive, emotional and social
functioning.
Figure 1 Overview of the interventions.
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EORTC QLQ-C30 scores were calculated according to
the scoring manual.18 Thus, a continuous scale score
ranging from 0 to 100 was calculated if the patient had
answered at least half of the items of the scale. A score
of 100 indicated the highest functioning. For interpret-
ation of EORTC QLQ-C30 results we set 10 units as the
minimally relevant scale contrast regardless of the
subscale.19 20
Eight ad hoc items from a piloted questionnaire were
pre hoc selected as the primary patient-evaluation end-
points (see table 3). Six items meant to determine infor-
mation and support from health professionals and
continuity of care were answered using the following
response categories: ‘Completely agree’, ‘Agree’, ‘Do
not agree’, ‘Completely disagree’ and ‘Do not know/
Not applicable’. Two items asked the patients to assess
the quality of care at the surgical department and in
general. These items used the following response cat-
egories: ‘Excellent’, ‘Very good’, ‘Good’, ‘Less good’
and ‘Bad’.
FOLLOW-UP
HRQoL and patient evaluations were assessed 8, 30 and
52 weeks after the patient’s inclusion with copies of the
same questionnaire that featured the EORTC QLQ-C30
items plus 64 other items. The questionnaires and the
reminders to non-responders (after 3 weeks) were sent
by ordinary mail. Non-response 6 weeks after the time of
the initial follow-up questionnaire prompted a reminder
phone contact. HRQoL was also assessed at baseline
using a questionnaire handed out at the hospital.
Sample size
Power calculations on the global health status scale
revealed that we needed responses from 116 patients in
each group (power of 90%, two-sided signiﬁcance level
of 5%, 1 : 1 allocation) to detect 10 units of difference
between groups. Due to inevitable drop-out, we aimed at
including a total of 280 patients.
Randomisation and allocation concealment
The two case managers undertook recruitment in turns.
After an assessment of inclusion and exclusion criteria,
potential patients were informed about the trial. Those
who were willing to participate were asked to ﬁll in a
consent form and the baseline questionnaire. Patients
returning these documents were randomised 1 : 1 by an
independent secretary using the minimisation tech-
nique21 and the SiMin software.22 To ensure comparable
groups in terms of characteristics possibly associated
with the outcomes, the following stratiﬁcation factors
were used: gender (male/female), cancer type (rectal
cancer/colon cancer) and age (<65/65–79/>79 years).
A random factor of 1 : 4 was used (ie, allocation included
20% randomness).
Group assignment was evident to the patients and the
case managers, but was blinded to the researchers.
Analyses
Analysis of covariance (ANCOVA), which in effect
adjusts each patient’s follow-up score for his or her base-
line score,23 was used to calculate the group difference
on each of the HRQoL subscales at each time of
follow-up. Analyses were accompanied by graphical pre-
sentations of the groups’ mean scores stratiﬁed by the
patients’ last consecutive questionnaire response. These
longitudinal graphical presentations served two pur-
poses: To provide an overview of all the data at the same
time; and to suggest whether any data complexity might
bias the statistical analyses.24
The patient evaluation answers were dichotomised
(‘Completely agree’ vs ‘the rest’ and ‘Excellent’ plus
‘Very good’ vs ‘the rest’). The positive proportion of
answers to each item was compared at each time of
follow-up using a generalised linear model with log link
for the Bernoulli family and robust variance; relative dif-
ferences are presented as prevalence proportion ratios
(PPRs).25
All analyses were conducted according to the
‘intention-to-treat’ principle, that is, patients were kept
in the analyses regardless of their ﬁnal diagnosis and
exposure to CM (decided by duration of treatment).
Statistical signiﬁcance was set at p≤0.05 and results
should be interpreted in awareness of multiple
comparisons.
To address potential attrition bias caused by uneven
attrition in the two groups,26 sensitivity analyses was con-
ducted, that is, data were analysed with adjustment for
the minimisation variables and categories. We did not
impute missing data because most missing data were
HRQoL and patient evaluations (outcome data) from
dead persons.
Primary endpoints were tested for subgroup-treatment
effect interaction as to cancer type, gender and age
using same categories as used in the minimisation.27
Due to the multiple testing, effect measure modiﬁcation
should be present at minimally two time points to be
accepted as an indication of a subgroup-treatment
effect.
All analyses were conducted with the use of Stata
V.11.2.
Ethics
The project was ethically acceptable to both control
group and intervention group patients because diagnos-
tics and treatment were unaffected, and we did not
know whether CM was superior to usual care. According
to the Danish Research Ethics Committee System,28 the
trial was not a biomedical intervention and did not need
the ethics committee’s approval. This was conﬁrmed by
correspondence with the chair of the regional ethics
committee. The Danish Data Protection Agency
approved the research database ( J.nr. 2008-41-2932).
The RCT was indexed at www.clinicaltrials.gov (ID
number: NCT00845247).
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RESULTS
Flow of participants
We assessed 532 patients for inclusion and included 280
patients. Online supplementary ﬁgure S2 shows the
reasons for non-participation and the group-wise ﬂow of
patients (ﬁgure 2). Table 1 shows that the patients in
the two groups were similar as to age, gender, disease
characteristics and self-reported variables at baseline.
The CM group had marginally higher mean baseline
HRQoL scores than the control group, except for cogni-
tive functioning.
Online supplementary ﬁgure S2 shows similar
response rates in the two groups at 8, 30 and 52 weeks.
Attrition occurred during the trial. Mortality 52 weeks
after inclusion was higher in the CM group (31 patients)
than in the control group (20 patients), but this differ-
ence was not statistically signiﬁcant and the two groups
appeared almost similar in terms of the remaining
patients’ characteristics (not shown). Importantly, no
clinically signiﬁcant differences between the unadjusted
and the adjusted estimates appeared.
HRQol
Table 2 presents the EORTC QLQ-C30 mean baseline
and follow-up scores at each time of follow-up and the
ANCOVA-calculated differences between the two groups.
No statistically signiﬁcant difference between groups
appeared on any subscale at any time point.
Online supplementary ﬁgure S3 offers a visual repre-
sentation of the EORTC QLQ-C30 scale scores by group
Figure 2 Trial profile
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and over time. Seventy-one per cent of all participants
(103 control group patients and 95 CM patients)
answered the baseline questionnaire and all answered
the three follow-up questionnaires (complete follow-up;
black markers and lines). Online supplementary
ﬁgure S3 shows that non-random drop-out applied to most
scales, that is, the non-responder group had statistically sig-
niﬁcantly lower scores at the assessment prior to non-
response than the responder group. The mean scores of
the two subgroups characterised by complete follow-up
appeared not to differ, and the proﬁles of the mean scores
changed similarly over time. The partial follow-up proﬁles
appeared less uniform, but plots were based on a
maximum of 20 responses per group (ﬁgure 3).
Patient evaluation of care
Table 3 shows the dichotomised patient evaluations at
week 8, 30 and 52. The two groups were almost identical
as to numbers of ‘Don’t know/ Not applicable’ answers
and skipped items so these ‘responses’ were omitted
from analyses. The PPRs of 23 of 24 items favoured the
CM group. Five, three and zero items differed statistically
signiﬁcant at week 8, 30 and 52, respectively.
We found no statistically signiﬁcant subgroup-
treatment effect interaction as to the global quality of
life-scale or the patient evaluation items.
DISCUSSION
Statement of principal findings
We found no effect of a manual-based CM intervention
on patients’ global health status or their functioning as
assessed from the EORTC QLQ-C30 questionnaire.
Patients of the CM group answered almost all (23 of 24)
patient evaluation items more positively than the control
group patients. The items regarding ‘the experience of
being continuously followed by a doctor or a nurse’, and
Table 1 Participants’ characteristics
Variable
Control group CM group
N=140 N=140
Mean age (SD) 66.2 (11.7) 66.3 (11.1)
Gender
Female 47 (33.6%) 47 (33.6%)
Male 93 (66.4%) 93 (66.4%)
Disease*
Colon cancer 72 (51.4%) 70 (50.0%)
Primary 62 58
Recurrent 10 12
Rectal cancer 64 (45.7%) 66 (47.1%)
Primary 47 48
Recurrent 17 18
Other cancer† 2 (1.4%) 2 (1.4%)
Not cancer† 2 (1.4%) 2 (1.4%)
Surgery*
No 16 (11.4%) 17 (12.1%)
Yes 124 (88.6%) 123 (87.9%)
Endoscopic surgery 10 5
Laparoscopic surgery 20 24
Laparotomy 94 94
One or more chronic disease‡ 73 (52.1%) 74 (52.9%)
Negative self-rated health status prior to current disease‡ 8 (5.8%) 11 (8.0%)
Living in partnership or married‡ 99 (72.3%) 103 (73.6%)
Income <33.500 EUR/year‡ 56 (41.2%) 51 (37.0%)
Without a job (senior citizen, unemployed etc.)‡ 90 (67.2%) 93 (67.9%)
EORTC QLQ-C30‡
Global quality of life 59.36 (25.54) 62.41 (22.96)
Physical functioning 80.96 (21.12) 83.39 (19.47)
Role functioning 67.78 (34.87) 69.71 (34.49)
Emotional functioning 71.88 (23.31) 72.56 (23.13)
Cognitive functioning 86.47 (16.55) 85.27 (21.13)
Social functioning 81.27 (24.95) 83.58 (22.51)
Data are means (SD) or numbers (%).
*Information found in medical records and hospital registers.
†Eight patients were falsely thought to suffer from colorectal cancer at the time of inclusion.
‡Reported by patients in the baseline questionnaire.
CM, case management; EORTC QLQ-C30, the European Organisation for Research and Treatment of
Cancer Core Quality of Life Questionnaire V.3.0
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Table 2 Mean baseline and mean follow-up scale scores and ANCOVA-calculated group differences
8 weeks (if baseline scale) 30 weeks (if baseline and 8 weeks scale) 52 weeks (if baseline, 8 and 30 weeks scale)
n-Control group: 116–119 n-Control group: 101–104 n-Control group: 96–99
n-CM group: 120–123 n-CM group: 102–107 n-CM group: 92–94
Baseline Follow-up Group difference Baseline Follow-up Group difference Baseline Follow-up Group difference
Mean (SD) Mean (SD) (95% CI) Mean (SD) Mean (SD) (95% CI) Mean (SD) Mean (SD) (95% CI)
Global quality of life
Control group 61.02 (25.90) 61.58 (21.43) 1.34 (−3.41 to 6.08) 64.90 (23.68) 71.15 (20.57) −0.91 (−5.91 to 4.09) 65.73 (22.19) 74.06 (21.17) −4.16 (−10.38 to 2.06)
CM group 64.58 (22.04) 64.38 (20.41) p=0.579 66.09 (21.02) 71.24 (21.58) p=0.720 67.21 (21.07) 70.56 (26.07) p=0.189
Physical functioning
Control group 84.16 (18.54) 73.69 (23.17) 0.27 (−4.65 to 5.18) 85.69 (17.05) 80.49 (21.52) −3.42 (−8.17 to 1.33) 86.53 (15.96) 83.90 (19.30) −2.04 (−6.46 to 2.38)
CM group 84.88 (18.45) 74.40 (21.63) p=0.915 86.29 (16.09) 78.08 (22.03) p=0.157 86.03 (16.30) 81.49 (19.68) p=0.363
Role functioning
Control group 70.26 (32.95) 53.30 (35.11) 1.91 (−6.47 to 10.29) 73.10 (31.36) 72.94 (31.34) −3.19 (−10.46 to 4.08) 74.48 (30.10) 80.03 (28.78) −2.29 (−9.97 to 5.40)
CM group 71.14 (33.61) 55.56 (35.37) p=0.654 74.37 (31.22) 71.23 (29.68) p=0.388 75.81 (31.04) 78.14 (27.47) p=0.558
Emotional functioning
Control group 73.00 (23.13) 76.18 (22.91) 3.35 (−1.41 to 8.11) 74.87 (21.69) 85.36 (18.94) −4.19 (−8.75 to 0.36) 75.62 (21.23) 86.22 (19.22) −2.08 (−7.56 to 3.40)
CM group 73.75 (22.43) 79.94 (22.13) p=0.167 75.05 (20.65) 82.34 (20.94) p=0.071 75.27 (20.68) 84.04 (21.01) p=0.455
Cognitive functioning
Control group 87.11 (16.73) 85.29 (19.55) 0.14 (−4.28 to 4.55) 88.46 (15.93) 85.42 (17.64) −0.36 (−4.47 to 3.76) 89.06 (15.09) 88.22 (15.84) −0.78 (−4.95 to 3.38)
CM group 87.98 (18.34) 85.93 (20.67) p=0.952 88.84 (16.38) 85.38 (18.36) p=0.864 89.36 (15.81) 87.59 (17.44) p=0.711
Social functioning
Control group 83.05 (23.77) 73.31 (25.89) 2.34 (−3.43 to 8.12) 85.92 (20.71) 83.17 (23.40) −2.86 (−8.24 to 2.52) 86.73 (20.30) 86.39 (22.49) −1.06 (−7.02 to 4.90)
CM group 84.44 (22.44) 76.45 (26.59) p=0.425 86.19 (20.21) 82.22 (23.14) p=0.295 87.10 (20.43) 85.48 (22.42) p=0.726
Patients included in week 30 analyses were all included in week 8 analyses. Patients included in week 52 analyses were all included in weeks 8 and 30 analyses.
CM, Case management
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‘conﬁdent about going home after surgery’ seemed, in
particular, to be more positively evaluated by CM
patients than by the control group. We found no statis-
tical indication that any subgroup (gender, age or
cancer type) beneﬁted differently from CM.
Strengths and weaknesses
The principal strength of this study was the comprehen-
sive, manual-based CM intervention performed in the
RCT design. A statement of the case managers’ activities
from the CM records and a debrieﬁng of the case man-
agers indicated that the CM intervention was conducted
according to the manual (reported in a paper submitted
to another journal).
Another strength was the use of the EORTC
QLQ-C30, which is the most used validated HRQoL
instruments in CRC settings and available in Danish.
EORTC QLQ-C30 focuses on domains relevant to most
cancer patients and minimally clinically relevant cross-
sectional contrasts have been proposed to guide the
interpretation of ﬁndings.19 In this study, all the conﬁ-
dence limits of the difference estimates were within ±10
units (after round off). We are therefore convinced that
we do not reject a clinically signiﬁcant effect of CM.
Patient evaluations were assessed using ad hoc items
which may be a potential weakness compared with
instruments with established measurement properties
and ‘benchmark scores’. The use of ad hoc items was
deemed necessary because existing relevant measures
were found to focus on either the inpatient or the out-
patient setting and not on care across care interfaces.
We argue that it is acceptable to analyse non-validated
items in a trial as long as items are presented by their
exact wording and analyses are conducted item by item.
This RCT was implemented with randomisation at the
patient level and with both patient groups being treated
at the same department at the same time. We acknow-
ledge that an intervention based on visibility and commu-
nication would have been more validly tested in a
cluster-randomised trial with randomisation performed
at department or hospital level. Anyway, the success of a
cluster randomised trial relies on its inclusion of several
treatment units which was hindered by our budget.29 The
two main limitations caused by the single unit set-up
were: (1) patient evaluations might have suffered from
information bias because patients had information about
the purpose of the trial and they were unblinded to
group assignment. To reduce information bias caused
by patients’ experience of ‘losing’ or ‘winning’ the ran-
domisation procedure, patients were neutrally informed
about the purpose of the trial at recruitment. In addition,
we believe patients over time ‘forgot’ about taking part in
a randomised study for which reason the patient evalua-
tions were unaffected by information bias. (2) The usual
staff noticed ‘effective’ CM actions which they tried to
‘copy’ to improve control group patients’ care (spill-over
effect). It is very unlikely that control group patients had
ongoing support and supervision, because this would
require organisational restructuring (eg, revised work
plans) or extra manpower, which did not take place.
A known problem when assessing patient-reported
outcomes is missing data and, as for HRQoL-data, non-
random dropout24 due to deaths. Importantly, although
more CM patients than control group patients were
dead at 52 weeks, online supplementary ﬁgure S3 does
Figure 3 Average EORTC
QLQ-C30 scale scores by group
and by length of follow-up.
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Table 3 Numbers and proportions () of patients taking a very positive or less positive stand, and the group differences.
Week 8 after inclusion Week 30 after inclusion Week 52 after inclusion
Very positive/less
positive
PPR
Very positive/less
positive
PPR
Very positive/less
positive
PPRPatient evaluation item
Usual
care CM
Usual
care CM
Usual
care CM
N=121 N=124 (95% CI) N=110 N=111 N=109 N=99 (95% CI)
Overall, the information was satisfactory 50 (0.43)/
67 (0.57)
58 (0.48)/
63 (0.52)
1.12
(0.85 to 1.49)
p=0.423
34 (0.33)/
70 (0.67)
50 (0.47)/
56 (0.53)
1.44
(1.03 to 2.03)
p=0.036*
36 (0.35)/
68 (0.65)
40 (0.42)/
56 (0.58)
1.20
(0.84 to 1.72)
p=0.307
Doctors and nurses have overall been
good at offering my family guidance,
counselling, support and help.
35 (0.36)/
63 (0.64)
40 (0.38)/
64 (0.62)
1.08
(0.75 to 1.55)
p=0.687
28 (0.29)/
67 (0.71)
33 (0.35)/
60 (0.65)
1.20
(0.79 to 1.82)
p=0.382
30 (0.33)/
61 (0.67)
32 (0.40)/
49 (0.60)
1.20
(0.80 to 1.79)
p=0.374
At no time have I been in doubt about who
to contact if I needed guidance,
counselling, support and help
55 (0.47)/
61 (0.53)
78 (0.63)/
45 (0.37)
1.34
(1.06 to 1.69)
p=0.015*
54 (0.50)/
55 (0.50)
60 (57)/46
(0.43)
1.14
(0.89 to 1.47)
p=0.302
45 (0.43)/
60 (0.57)
47 (0.48)/
50 (0.52)
1.13
(0.84 to 1.53)
p=0.426
In my experience, a doctor or a nurse from
the hospital has been there for me through
my entire treatment course
51 (0.45)/
63 (0.55)
73 (0.60)/
49 (0.40)
1.34
(1.04 to 1.72)
p=0.023*
46 (0.43)/
60 (0.57)
68 (65)/36
(0.35)
1.51
(1.16 to 1.95)
p=0.002*
42 (0.41)/
61 (0.59)
46 (0.47)/
52 (0.53)
1.15
(0.84 to 1.58)
p=0.381
When I was discharged after surgery, I felt
confident about going home
34 (0.36)/
61 (0.64)
53 (0.54)/
46 (0.46)
1.50
(1.08 to 2.07)
p=0.016*
34 (0.35)/
63 (0.65)
49 (0.49)/
51 (0.51)
1.40
(1.00 to 1.96)
p=0.052*
34 (0.36)/
61 (0.64)
43 (0.48)/
47 (0.52)
1.33
(0.95 to 1.89)
p=0.102*
In my experience, my treatment course
has been coherent
41 (0.36)/
74 (0.64)
57 (0.48)/
61 (0.52)
1.35
(0.99 to 1.85)
p=0.054
39 (0.38)/
65 (0.62)
52 (50)/53
(0.50)
1.32
(0.96 to 1.81)
p=0.084
36 (0.35)/
66 (0.65)
41 (0.44)/
52 (0.56)
1.25
(0.88 to 1.77)
p=0.212
How do you assess the quality of your
investigation and treatment at Department
P so far?
89 (0.76)/
28 (0.24)
105 (0.88)/
15 (0.12)
1.15
(1.02 to 1.30)
p=0.025*
89 (0.82)/
19 (0.18)
96 (88)/13
(0.12)
1.07
(0.96 to 1.19)
p=0.242
88 (0.85)/
16 (0.15)
85 (0.88)/
12 (0.12)
1.04
(0.93 to 1.16)
p=0.537
How do you assess the quality of your overall
diagnostics and treatment so far?
85 (0.71)/
35 (0.29)
95 (0.77)/
28 (0.23)
1.09
(0.94 to 1.27)
p=0.258
77 (0.70)/
33 (0.30)
85 (78)/24
(0.22)
1.11
(0.95 to 1.30)
p=0.181
75 (0.70)/
32 (0.30)
68 (0.69)/
30 (0.31)
0.99
(0.83 to 1.19)
p=0.913
A PPR>1 indicates that more CM patients than control group patients concurred with the item.
Numbers of ‘Don’t know/ Not applicable’ and missing answers were comparable and have been omitted.
CM, case management; PPR, prevalence proportion ratio.
* p≤0.05 in the sensitivity analyses (including adjustment for gender, cancer type and age group).
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not indicate that we have overlooked a positive effect of
CM on the global health status, physical functioning or
the role functioning subscales due to non-random
drop-out. On the other hand, the emotional function-
ing, cognitive functioning and social functioning differ-
ences might have been biased favouring the control
group as a consequence of excess deaths in the CM
group. Thus, online supplementary ﬁgure S3 insinuates
that the CM patients who withdrew between weeks 30
and 52 might already have experienced diminishing
functioning on these scales at 30 weeks.
Although the baseline questionnaire was returned
before the concealed randomisation, CM patients had
higher mean baseline scores on ﬁve of the six EORTC
QLQ-C30 subscales than the control group patients.
Importantly, ANCOVA appropriately handles such ‘by
chance problem’ without introducing bias.23
Despite multiple comparisons, p≤0.05 was generally
used as the level of statistical signiﬁcance. Importantly,
even if we had adjusted the p values to counteract the
problem of multiple comparisons we would still report
the tendency towards improved patient evaluations in
the CM group.
Generalisability
Non-participants and participants differed in terms of
cancer type and age. The group of CM participants
counted statistically more rectal cancer patients than
the usual care group and they were slightly, but statistically,
signiﬁcantly older. The primary reason for this was that
another study included patients suffering from primary
non-metastatic rectal cancer, who we thus could not
include.
The results can be generalised to a wider group of
cancer patients, primarily for two reasons: (1) inter-
action analyses indicated that no particular subgroup
(gender, age or cancer type) beneﬁted from CM and
(2) previous research has shown that patients suffering
from different cancer types face identical psychosocial
problems and healthcare system-related barriers.30 31
Comparisons with other studies and meaning of the study
The present study found that CM improved patient eva-
luations of care even if attrition over time reduced the
power of the analyses. Improved patient evaluations have
also been reported in other CM RCTs.32–34 The consist-
ent ﬁnding of improved patient evaluations despite the
use of different measures is important because patient
evaluations may be seen as a quality criterion at par with
‘technical quality’ and objective outcomes.35
Observational and qualitative studies including CRC
patients have found that patients’ care evaluations cor-
relate positively with their HRQoL.8 9 Anyway, based on
the ‘neutral ﬁndings’ in present and previous CM
trials,32 36 37 one may speculate whether it is possible for
case managers to improve cancer patients’ HRQoL
during the treatment phase. One explanation may be
that CM does not alleviate the impact of cancer
symptoms, adverse treatment effects and the existential
concerns on patients’ HRQoL. Another plausible
explanation is poor responsiveness of the existing
HRQoL instruments in the ‘new’ settings they have been
applied.38 Retrospectively, we regret that we did not con-
sider including an anchor item in our questionnaire for
the purpose of responsiveness analyses of the EORTC
QLQ-C30 in the setting and context of present trial.
Unanswered questions and future research
This CM study focused on patient-reported outcomes.
CM may also be implemented to reduce the amount of
‘inappropriate’ healthcare services (duplicated services,
unplanned readmissions and out-of-hours services) or
if it enhances information transfer and professional col-
laboration around the patient. Yet, these issues remain
to be explored.
CONCLUSIONS
In this RCT of CRC patients undergoing treatment, we
found no impact of hospital-based CM on patients’
HRQoL at week 8, 30 or 52 after inclusion, but several
patient evaluation items were statistically signiﬁcantly
improved by CM, and a tendency towards better patient
evaluations in the CM group than in the usual care
group was observed.
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